{"organizations": [], "uuid": "edad374d3c178658cf49d0bb5731ba3319f27b7f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/26/globe-newswire-minerva-neurosciences-to-report-first-quarter-2018-financial-results-and-business-updates-on-may-3-2018.html", "country": "US", "domain_rank": 767, "title": "Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-26T16:30:00.000+03:00", "replies_count": 0, "uuid": "edad374d3c178658cf49d0bb5731ba3319f27b7f"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/26/globe-newswire-minerva-neurosciences-to-report-first-quarter-2018-financial-results-and-business-updates-on-may-3-2018.html", "ord_in_thread": 0, "title": "Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "waltham", "sentiment": "none"}], "organizations": [{"name": "minerva neurosciences", "sentiment": "negative"}, {"name": "minerva neurosciences, inc.", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}, {"name": "minerva neurosciences minerva neurosciences, inc.", "sentiment": "none"}, {"name": "investors and media", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2018 on Thursday, May 3, 2018. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.\nThe live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 8885379. A live webcast of the conference online in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com . The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 30 days.\nAbout Minerva Neurosciences\nMinerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: roluperidone (MIN-101), in Phase 3 clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922) in Phase 2b clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com .\nContact :\nWilliam B. Boni\nVP, Investor Relations\nCorp. Communications\nMinerva Neurosciences, Inc.\n(617) 600-7376\nSource:Minerva Neurosciences, Inc", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/69e604cb-25b6-4235-ae9a-17c25cc158b9", "https://www.globenewswire.com/Tracker?data=Efr93n8ABuOGBAvS-qsHv2nEXh5mbzSdKUx0wno6InBEL-NyGBm9JVwQSGqLpeMl0GtqGDJ0yKRE5dIU9YJuIXubYkj2ZySh2sa1z8rFJ4G_Io7LCR6mXtg_M6wLyHkb"], "published": "2018-04-26T16:30:00.000+03:00", "crawled": "2018-04-26T17:29:07.019+03:00", "highlightTitle": ""}